We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Nanopore Sequencing and Machine Learning Powered-Platform Enables High-Accuracy, High-Frequency COVID-19 Testing

By LabMedica International staff writers
Posted on 14 Oct 2020
A newly-launched nanopore sequencing and machine learning powered platform enables high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing, allowing businesses, educational institutions, and other points of frequent gathering to resume operations safely.

The new AMPD platform launched by Angstrom Bio, Inc. More...
(Austin, TX, USA) leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza. At the heart of AMPD is a novel nucleotide chemistry and computational biology platform designed to harness the bandwidth and resolution of Oxford Nanopore Technologies’ (Oxford, UK) nanopore Third-Generation Sequencing (TGS) systems. Unlike diagnostic systems that rely upon fluorescence-driven workflows for diagnostic analysis, nanopore TGS counts individual DNA molecules that pass through each of hundreds of nano-scale pores in a specially-designed membrane. The combination of single-molecule resolution and parallelism allow for the processing of tens of thousands of diagnostic results per AMPD run, while enabling orders of magnitude greater sensitivity than is currently available. This makes AMPD ideal for parties that require timely access to affordable, repeated testing, but that cannot compromise safety.

AMPD utilizes a simple, self-collected saliva sample that not only avoids the discomfort associated with traditional swabs. Samples are registered and collected on-site using simple workflows then processed in an automated AMPD facility, with results delivered within 24 hours. Angstrom intends to bring more than one million results per day online in 2021, at prices that enable nearly any organization to have access to repeated, high-quality testing.

“By leveraging the extraordinary resolution and bandwidth of nanopore sequencing and the power of our machine learning-driven diagnostic pipelines, and by rethinking pre-COVID-19 diagnostic workflows, we have been able to design a platform that can provide the extreme scale and accuracy required to meet the unprecedented challenges posed by COVID-19,” said Carlos F. Santos, Ph.D., Angstrom's CEO.

Related Links:
Angstrom Bio, Inc.
Oxford Nanopore Technologies



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.